n-Lorem Foundation Partners with Alnylam to Expand Technology Access to RNAi Therapeutics for Patients with Nano-rare Diseases
Alnylam’s RNAi expertise and financial donation bolster efforts to reach more nano-rare patients where a RNAi targeted approach would be most appropriate SAN DIEGO--(BUSINESS WIRE)--#ASO--n-Lorem, a nonprofit Foundation, discovering and providing experimental antisense oligonucleotide (ASO) medicines to nano-rare disease patients (1 to 30 patients worldwide) for free, for life, today…